(Q36570549)

15 August 2017

1 reference

title

Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). (English)

1 reference

15 August 2017

1 reference

1 reference

31

G Passalacqua

1 reference

15 August 2017

Giorgio Walter Canonica

8

object named as

G W Canonica

1 reference

15 August 2017

15

S Durham

1 reference

15 August 2017

19

M L Kowalski

1 reference

15 August 2017

41

B Yawn

1 reference

15 August 2017

37

F E R Simons

1 reference

15 August 2017

J Bousquet

1

1 reference

15 August 2017

P van Cauwenberge

2

1 reference

15 August 2017

N Aït Khaled

3

1 reference

15 August 2017

C Bachert

4

1 reference

15 August 2017

C E Baena-Cagnani

5

1 reference

15 August 2017

J Bouchard

6

1 reference

15 August 2017

C Bunnag

7

1 reference

15 August 2017

K-H Carlsen

9

1 reference

15 August 2017

Y-Z Chen

10

1 reference

15 August 2017

A A Cruz

11

1 reference

15 August 2017

A Custovic

12

1 reference

15 August 2017

P Demoly

13

1 reference

15 August 2017

R Dubakiene

14

1 reference

15 August 2017

W Fokkens

16

1 reference

15 August 2017

P Howarth

17

1 reference

15 August 2017

J Kemp

18

1 reference

15 August 2017

V Kvedariene

20

1 reference

15 August 2017

B Lipworth

21

1 reference

15 August 2017

R Lockey

22

1 reference

15 August 2017

V Lund

23

1 reference

15 August 2017

S Mavale-Manuel

24

1 reference

15 August 2017

E O Meltzer

25

1 reference

15 August 2017

J Mullol

26

1 reference

15 August 2017

R Naclerio

27

1 reference

15 August 2017

K Nekam

28

1 reference

15 August 2017

K Ohta

29

1 reference

15 August 2017

N Papadopoulos

30

1 reference

15 August 2017

R Pawankar

32

1 reference

15 August 2017

T Popov

33

1 reference

15 August 2017

P Potter

34

1 reference

15 August 2017

D Price

35

1 reference

15 August 2017

G Scadding

36

1 reference

15 August 2017

V Spicak

38

1 reference

15 August 2017

E Valovirta

39

1 reference

15 August 2017

D-Y Wang

40

1 reference

15 August 2017

O Yusuf

42

1 reference

15 August 2017

GA2LEN

43

1 reference

15 August 2017

language of work or name

1 reference

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

61

1 reference

15 August 2017

9

1 reference

15 August 2017

1086-1096

1 reference

Allergic rhinitis and its impact on asthma

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Levocetirizine better protects than desloratadine in a nasal provocation with allergen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Sedation and performance impairment of diphenhydramine and second-generation antihistamines: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Intrasinus administration of topical budesonide to allergic patients with chronic rhinosinusitis following surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effect of amoxicillin-clavulanate in clinically diagnosed acute rhinosinusitis: a placebo-controlled, double-blind, randomized trial in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Advances in H1-antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Pharmacy benefits and the use of drugs by the chronically ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Comparative Effects of Desloratadine versus Montelukast on Asthma Symptoms and Use of β<sub>2</sub>-Agonists in Patients with Seasonal Allergic Rhinitis and Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis--a pooled analysis of three studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Hypothalamic-pituitary-adrenal axis function after inhaled corticosteroids: unreliability of urinary free cortisol estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effects of three nasal topical steroids in the intraocular pressure compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Inhaled and Nasal Corticosteroid Use and the Risk of Fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Allergic contact dermatitis in response to budesonide reactivated by inhalation of the allergen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Contact allergy to corticosteroids in patients using inhaled or intranasal corticosteroids for allergic rhinitis or asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Fluticasone propionate aqueous nasal spray in pregnancy rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

The effects of montelukast on intradermal wheal and flare

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

The effect of omalizumab on nasal allergic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Omalizumab inhibits allergen challenge-induced nasal response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Perennial rhinitis in the under 4s: a difficult problem to treat safely and effectively? A comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

Lack of clinically relevant interaction between desloratadine and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2006.01144.X

10.1111/J.1398-9995.2006.01144.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference